By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



New York Division
90 Park Avenue
New York City  New York  10016-1301  U.S.A.
Phone: 212-551-4000 Fax:

Sanofi-Synthelabo is a global healthcare company. With annual sales in excess of $5.5 billion and 30,000 employees in more than 100 countries, Sanofi-Synthelabo ranks among the world's top 20 pharmaceutical companies and the top seven pharmaceutical companies in Europe. World headquarters are in Paris, France. U.S. headquarters are in New York City.

In the U.S., as in other major markets, the principle area of business of Sanofi-Synthelabo is ethical pharmaceuticals. Core therapeutic areas are cardiovascular disease and thrombosis, diseases of the central nervous system, cancer, and internal medicine.

The foundation of Sanofi-Synthelabo's worldwide growth is a highly regarded Research and Development program, with about 50 compounds under development, half of which are in Phase II and Phase III. Sanofi-Synthelabo has more than 6,000 scientists and R&D support staff in Europe and the U.S.

As we continue intensifying our selling efforts in the U.S., we're planning to add 1,000 more Sales Professionals to a Sales Force that has already doubled in size in just the last two years. In addition, we have a number of Division Manager career opportunities available in select markets throughout the country.

Join us in our fight for health. Healthy sales are sure to follow.

Last Updated 8-29-01

Key Statistics

Ownership: Public

Web Site: Sanofi-Synthelabo
Symbol: SNY




Human Genome Sciences, Inc.  Human Gene Consortium Partners

Company News
Sanofi-Aventis Japan To Merge Sanofi-Synthelabo (SNY) And Aventis Pharma Japan In January 11/2/2005 11:43:21 AM
Sanofi-Aventis (France) (SASY.PA) Filing Of The Form 20-F And "Document de Reference"10/19/2005 5:13:16 PM
The Day In Review: Biotech Ends Winning Streak10/19/2005 5:13:15 PM
Dendrite International, Inc. (DRTE) Signs Agreement With The Sanofi-Aventis (SASY.PA) Group To Support Its Newly Combined US Sales Force10/19/2005 5:13:15 PM
Sanofi Pasteur (SASY.PA) New Polio Vaccine Licensed For Use In Novel Approach To Global Eradication Efforts10/19/2005 5:13:11 PM
Sanofi-Aventis (France) (SASY.PA) Release: Rescheduling Of The Pre-Trial Order Date In The United States Plavix(R) Litigation10/19/2005 5:13:10 PM
Vical Incorporated (VICL) Announces Issuance Of Core Technology Patents In Canada10/19/2005 5:13:10 PM
Sanofi-Aventis (US Headquarters) (SNY) Joins The Fight Against Tuberculosis In South Africa10/19/2005 5:13:06 PM
Court Grants Sanofi-Aventis (US Headquarters) (SNY) Request For Order Of Prohibition In The Canadian Plavix(R) Litigation10/19/2005 5:13:06 PM
Sanofi-Aventis (US Headquarters) (SNY) Release: New Data Demonstrate Alvesco(R) (ciclesonide) Has A Low Incidence Of Mouth- And Throat-Related Side Effects In Pediatric Asthma Patients10/19/2005 5:13:06 PM